Massachusetts Finalizes Regulations and Code of Conduct for Medical Device and Pharmaceutical Relationships with Health Care Practitioners
Client Alert | 1 min read | 03.13.09
This week, Massachusetts approved regulations creating a new state-authored marketing code of conduct for interactions between health care practitioners and pharmaceutical and medical device manufacturers. The regulations are effective on July 1, 2009.
The regulations require manufacturers to designate a compliance officer and establish compliance and training programs. The regulations also require manufacturers to adopt a code of conduct, which incorporates voluntary industry codes adopted by the Pharmaceutical Research and Manufacturers of America and the Advanced Medical Technology Association. Notably, the state-mandated code of conduct incorporates requirements in addition to these two voluntary industry codes and explicitly restricts a broad variety of conduct, including a ban on providing items such as pens and mugs.
The subject of much debate among stakeholders, the new regulations also establish reporting requirements for certain payments made to "covered recipients," including mandating that manufacturers report certain payments exceeding a $50 threshold made to healthcare practitioners, hospitals, nursing homes, pharmacists and health benefit plan administrators. The $50 limit is not cumulative but calculated on an individual transactional basis. The law does provide for several disclosure exemptions, such as certain payments made in conjunction with research and clinical trials, demonstration or evaluation units, and rebates and discounts; however, several categories of indirect payments are not exempt, including charitable donations to universities or hospitals, sponsorship of continuing medical education, and third-party professional or scientific meetings or conferences. The first disclosure reports are due on July 1, 2010.
Insights
Client Alert | 3 min read | 11.21.25
On November 7, 2025, in Thornton v. National Academy of Sciences, No. 25-cv-2155, 2025 WL 3123732 (D.D.C. Nov. 7, 2025), the District Court for the District of Columbia dismissed a False Claims Act (FCA) retaliation complaint on the basis that the plaintiff’s allegations that he was fired after blowing the whistle on purported illegally discriminatory use of federal funding was not sufficient to support his FCA claim. This case appears to be one of the first filed, and subsequently dismissed, following Deputy Attorney General Todd Blanche’s announcement of the creation of the Civil Rights Fraud Initiative on May 19, 2025, which “strongly encourages” private individuals to file lawsuits under the FCA relating to purportedly discriminatory and illegal use of federal funding for diversity, equity, and inclusion (DEI) initiatives in violation of Executive Order 14173, Ending Illegal Discrimination and Restoring Merit-Based Opportunity (Jan. 21, 2025). In this case, the court dismissed the FCA retaliation claim and rejected the argument that an organization could violate the FCA merely by “engaging in discriminatory conduct while conducting a federally funded study.” The analysis in Thornton could be a sign of how forthcoming arguments of retaliation based on reporting allegedly fraudulent DEI activity will be analyzed in the future.
Client Alert | 3 min read | 11.20.25
Client Alert | 3 min read | 11.20.25
Client Alert | 6 min read | 11.19.25
